Company: TAK
Filing Date: 2025-06-02
Form Type: 6-K
Source: 0001395064-25-000071
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-02
Form: 6-K
Chunk 1
---
ide, Showing Reductions in Phlebotomy,</div>

#### Improved Hematocrit Control in Polycythemia Vera

#### OSAKA, Japan, June 2, 2025 –
Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced on June 1, 2025 (CST), at American Society of Clinical Oncology (ASCO) Annual Meeting, detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. Please see the attached press release for details.

The topline results of this study were disclosed on March 3, 2025, in “Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera”.

| Media Contact:        |     | Investor Contact:              |
| Emy Gruppo            
 emy.gruppo@takeda.com |     | Christopher O’Reilly           
 christopher.oreilly@takeda.com |

The impact on Takeda’s financial results for the fiscal year ending March 31, 2026 (FY2025), following the study results, is immaterial.

<div align='center'>###</div>

News Release

<div align='center'>Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera</div>

− Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint

− All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes

− No serious adverse events considered related to rusfertide were reported

− Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA

NEWARK